Immutep Ltd has released a press release.
Phase II TACTI-002 trial recruitment successfully completed
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immutep
- Immutep Global Webcast Slides to Discuss Clinical Results
- Immutep announces publication of SITC 2021 posters
- Immutep announces publication of SITC 2021 abstracts
- Immutep granted Chinese Patent for eftilagimod alpha
- Immutep receives EMA scientific advice for Phase 3 in MBC
Later from Immutep
- Good safety reported from 1st five patients in INSIGHT-003
- Immutep Advances IMP761 Manufacturing
- Australian Patent Granted for Efti with PD-1 Inhibitors
- Immutep receives FDA feedback for Efti development in MBC
- Japanese patent granted for LAG-3 antibody LAG525
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep